A Trial to Assess Steviol Glycosides on Acute Appetite Hormone Release

NACompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

April 15, 2022

Primary Completion Date

June 5, 2024

Study Completion Date

June 5, 2024

Conditions
Overweight and ObesityType 2 Diabetes Mellitus
Interventions
OTHER

Water

Each subject will receive one control and three treatments in the crossover design. The control contains water only.

OTHER

Glucose

Each subject will receive one control and three treatments in the crossover design. The glucose contains water and glucose.

OTHER

Steviol Glycosides

Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside beverage contains water and steviol glycosides.

OTHER

Steviol Glycosides plus glucose

Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside plus glucose beverage contains water, glucose, and steviol glycosides.

OTHER

Rebaudioside A

A leaf-based, extracted stevia product to compare to the Eversweet in the normal weight group only. The Rebaudioside A contains water and rebaudioside A.

Trial Locations (3)

33169

Excellence Medical and Research, Miami Gardens

34102

Advanced Research for Health Improvement, Naples

60625

Great Lakes Clinical Trials, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cargill

INDUSTRY

lead

Midwest Center for Metabolic and Cardiovascular Research

OTHER

NCT05287906 - A Trial to Assess Steviol Glycosides on Acute Appetite Hormone Release | Biotech Hunter | Biotech Hunter